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Abstract: We report herein a simple and efficient two-step synthetic approach to new  
2-trichloromethylquinazolines possessing a variously substituted sulfonamide group at 
position 4 used to prepare new quinazolines with antiparasitic properties. Thus, an original 
series of 20 derivatives was synthesized, which proved to be less-toxic than previously 
synthesized hits on the human HepG2 cell line, but did not display significant 
antiplasmodial activity. A brief Structure-Activity Relationship (SAR) evaluation shows 
that a more restricted conformational freedom is probably necessary for providing 
antiplasmodial activity. 
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1. Introduction 
The quinazoline ring is an important molecular scaffold whose derivatives display a wide variety  
of pharmacological properties. Indeed, they were used as potent tyrosine kinase and cellular 
phosphorylation inhibitors [1], and they also act as ligands of benzodiazepine and GABA receptors in 
the central nervous system (CNS) [2] or as DNA binders [3]. Some of them exhibit remarkable activity 
as anticancer [4–6], antiviral [6–8], antibacterial [9] and anti-TB agents [10,11]. Moreover, popular 
drugs containing the quinazoline unit are available on the market. For example, erlotinib and gefitinib 
are used as epidermal growth factor receptor inhibitors in the treatment of several types of tumors [12], 
especially lung cancer [13,14]. In the other hand, prazosin acts as an α-adrenergic blocker and is used 
to treat high blood pressure [15]. In continuation of our research program centered on the design and 
synthesis of original molecules with pharmacological properties [16–19], our group recently described 
the preparation of new 4-substituted-2-trichloromethylquinazoline derivatives which exhibit original  
in vitro antiplasmodial properties [20–24]. The promising results displayed by these recent studies 
prompted us to synthesize new derivatives in this 2-trichloromethylquinazoline series in order to 
identify both more potent antiplasmodial derivatives and less toxic ones, in order to increase the 
selectivity index (SI). With this objective, we focused on the synthesis of N-(quinazolin-4-
yl)benzenesulfonamides, taking into account that the sulfonamide group is well-known for its 
pharmaceutical interest in the field of anti-infectious substances.  
2. Results and Discussion 
2.1. Synthesis 
Earlier works described the synthesis of N-(quinazolin-4-yl)benzenesulfonamides by nucleophilic 
substitution of 4-methoxyquinazoline by the sulfanilamide anion [9], by the construction of the 
quinazoline core from N-arylimidines and N-tosylisocyanodichloride [25] or by reacting p-toluene-
sulfonylisothiocyanate with 2-arylquinazoline-4(3H)-thione [26].  
More recent publications report the access to these sulfonamides from the readily available  
4-chloroquinazoline derivatives. Aryl-sulfonamides 2 in the presence of bases such as sodium hydride 
or potassium t-butoxide underwent nucleophilic substitution of 4-chloroquinazoline 1 and afforded the 
desired compound 3 in limited yields [27,28] (Scheme 1).  
It is worth mentioning that this reaction was never attempted starting from 4-chloro-2-trichloro-
methylquinazoline [29]. Although the yields obtained with this strategy remained low, we tried to 
perform this reaction using p-toluenesulfonamide. Unfortunately, in our hands, whatever the operating 
conditions applied only traces of product were detected with LC-MS (Scheme 2). 
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Scheme 1. Synthesis of sulfonamide 3 starting from 4-chloroquinazoline 1. 
 
Scheme 2. Synthesis of sulfonamide 6 starting from 4-chloro-2-trichloromethylquinazoline (4). 
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Reaction conditions: (i) K2CO3, PEG-400, 130 °C, MW; (ii) K2CO3, DMF, 130 °C, MW; (iii) NaH, 
DMF, 80 °C; (iv) neat, 140 °C. 
Facing these failures, we chose to reverse the strategy by reacting readily available sulfonyl 
chlorides with 4-amino-2-trichloromethylquinazoline (7). We therefore investigated first of all the 
optimal synthesis of the key intermediate derivative 7 (Scheme 3). 
Scheme 3. Synthesis of 4-amino-2-trichloromethylquinazoline (7). 
N
N
Cl
CCl3 N
N
CCl3
NH2
i, ii, iii or iv
4 7  
Reaction conditions: (i) NH4OH 25% in H2O, traces; (ii) NH3 2 M in MeOH, 3 days, rt, 91% 
(Method A); (iii) NH3 0.5 M in dioxane, 140 °C, 15 min, MW, 44%; (iv) NH3 0.4 M in THF, 140 °C, 
15 min, MW, 100% (Method B). 
The reaction of 4-chloro-2-trichloromethylquinazoline (4) with 25% aqueous ammonium hydroxide 
led to the predominant formation of 2-trichloromethylquinazolin-4(3H)-one [23] accompanied by 
traces of the expected amino derivative 7, so it appeared that it was necessary to operate under 
anhydrous conditions to prevent hydrolysis. Thus, the use of a solution of 2N ammonia in dry 
methanol afforded the expected amino derivative 7 in 71% yield after 24 h at room temperature. 
Increasing the time of the reaction up to 72 h increased the yield to 91% (Method A), while elevating 
the temperature with a view to shortening reaction time was detrimental and led mainly to the 
formation of 4-methoxy-2-trichloromethylquinazoline. In order to prevent this side reaction, due to the 
nucleophilic character of methanol, the amination must be conducted in a solvent inert towards the 
starting material 4. In order to shorten the reaction time we investigated the benefit of using sealed 
vials under microwave irradiation. Thus, under such conditions, the use of ammonia in dioxane (0.5 M, 
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3 equiv.) afforded 7 in only 44% yield at 140 °C. Finally, we found that heating 4 under the same 
conditions in THF (0.4 M, 3 equiv.) led to 7 in quantitative yield after only 15 min (Method B) which 
is not surprising given the known ability of THF to absorb microwaves.  
Having secured good access to this key intermediate 4-amino-2-trichloromethylquinazoline (7), we 
next synthesized the target sulfonamides using variously substituted sulfonyl chlorides (Scheme 4) 
with a view to further study the influence of the substituent nature on the biological properties. Amino 
derivative 7 was reacted with an excess of sodium hydride in THF. The so-formed anion was then 
trapped with sulfonyl chloride. The resulting sulfonamides 8 were thus obtained in good yields (Table 1) 
without requiring any chromatographic purification (except for compound 8t). 
Scheme 4. Synthesis of N-(2-trichloromethylquinazolin-4-yl)sulfonamides 8. 
 
Table 1. Reaction yields and biological evaluation for sulfonamides 8a–t. 
Entry R-  Product Yield % CC50 (µM) a IC50 PfK1 (µM) b 
1 Ph- 8a 62 82.0 >10 * 
2 4-Me-Ph- 8b 51 68.7 >10 * 
3 4-MeO-Ph- 8c 56 102.3 >10 * 
4 4-CN-Ph- 8d 73 73.8 >10 * 
5 4-Cl-Ph 8e 50 71.1 >10 * 
6 4-Br-Ph- 8f 60 57.4 >10 * 
7 4-F-Ph- 8g 66 69.5 >10 * 
8 3-F-Ph- 8h 53 106.4 >10 * 
9 2-F-Ph- 8i 60 136.1 >10 * 
10 4-NO2-Ph- 8j 91 88.3 >10 * 
11 3-NO2-Ph- 8k 56 119.8 >10 * 
12 2-NO2-Ph- 8l 59 126.0 >10 * 
13 4-CF3-Ph- 8m 88 49.0 >10 * 
14 3-CF3-Ph- 8n 100 75.1 >10 * 
15 2-CF3-Ph- 8o 50 73.8 >10 * 
16 Biphenyl-4-yl 8p 23 38.2 >10 * 
17 Napht-2-yl- 8q 43 48.8 >10 * 
18 Napht-1-yl- 8r 61 47.8 >10 * 
19 Thiophen-2-yl- 8s 43 121.1 >10 * 
20 Methyl- 8t 18 241.2 >10 * 
Doxorubicine a 0.2 - 
Chloroquine b 30 0.6 
Doxycycline b 20 6.0 
a Doxorubicine was used as a cytotoxic reference-drug; b chloroquinine and doxycycline were used 
as antimalarial reference-drugs; * Tested compounds did not show significant antiplasmodial 
activity at the highest tested concentration (10 µM). 
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Our efficient two-step methodology afforded the expected compounds in a 50–100% range yield 
except for the biphenyl-4-yl-, napht-2-yl, thiophen-2-yl  and the methyl derivatives (compounds 8p, 
8q, 8s and 8t, respectively, entries 16, 17, 19 and 20) which were not obtained from simple 
benzenesulfonyl chlorides. One the one hand, the electron withdrawing or donating character of the 
substituent of benzenesulfonyl chlorides did not affect appear to notably the reaction yield. However, 
entries 4, 10, 13 and 14 corresponding to electron withdrawing groups are the ones which gave the best 
yields. On the other hand, the lowest reaction yields are attributable to the purification process (namely 
the high solubility of molecules 8p–t in CH2Cl2). 
2.2. Biological Evaluation and Structure-Activity Relationship (SAR) Study 
Following previously reported experimental procedures [22,23], the in vitro antiplasmodial activity 
toward the multi-resistant W2 or K1 Plasmodium falciparum strains was measured by determining the 
IC50 (inhibition concentration 50% in µM) and comparing them with two commercial reference-drugs: 
chloroquine and doxycycline. The cytotoxicity was measured toward the human HepG2 cell line by 
determining the CC50 (cytotoxic concentration 50% in µM) and comparing them with doxorubicine 
used as a cytotoxic reference-drug. Concerning the biological evaluation, this series showed excellent 
solubility in biological media, contrary to the 4-thiophenoxy- series [22] whose cytotoxic evaluation 
was limited by a lack of solubility (Table 2, entry 4). 
Table 2. Antiplasmodial and cytotoxicity evaluation in 2-trichloromethylquinazoline series. 
Entry Structure CC50 HepG2 (µM) IC50 P. falc. (µM) SI a
1 
N
N
CCl3
F
 
>125 2.5 >50 
2 
N
N
CCl3
N
H
Cl Cl
16 0.4 40 
3 
N
N
CCl3
O
Cl
50 1.1 45 
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Table 2. Cont. 
Entry Structure CC50 HepG2 (µM) IC50 P. falc. (µM) SI a 
4 
N
N
CCl3
S
Cl
>25 0.9 >28 
5 
N
N
CCl3
NH
S
O
O
R
49–136 >10 nd 
Doxorubicine b 0.2 - - 
Chloroquine c 30 0.6  
Doxycycline c 20 6.0  
a Selectivity index (SI) was calculated according to the formula: SI = CC50/IC50; b Doxorubicine was 
used as a cytotoxic reference-drug; c Chloroquinine and Doxycycline were used as antimalarial 
reference-drugs. 
Unfortunately, contrary to the previously synthesized series (Table 2, entries 1–4), the sulfonamide 
derivatives (Table 1 and Table 2, entry 5) did not display significant antiplasmodial activity with IC50 
values >10 µM. The Structure-Activity Relationship study seems to indicate that the introduction of a 
sulfonamide group at position 4 of the quinazoline ring leads to a larger gap between the phenyl 
substituent and the quinazoline ring. This structural change added a more important conformational 
freedom and reduced antiplasmodial activity. The most potent antiplasmodial molecule previously 
synthesized (Table 2, entry 2) displayed slight cytotoxicity (16 µM) on the HepG2 human cell line 
which limits its selectivity index to 40. Concerning the sulfonamide derivatives, apart from the 
biphenyl derivative 8p (Table 1), this series appeared less-toxic than previously synthesized hits on the 
same cell line.  
Thus, taking advantage of this brief SAR evaluation, two new 4-substituted quinazoline series 
presenting a more restricted conformational freedom (Figure 1) could be prepared by using the 
synthetic approach presented herein, in order to identify new antiplasmodial hits.  
Figure 1. Novel investigated derivatives. 
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3. Experimental  
3.1. General Procedures 
Commercial reagents were used as received without additional purification. Melting points were 
determined on a Köfler melting point apparatus and are uncorrected. Elemental analyses and HRMS 
were carried out at the Spectropole, Faculté des Sciences et Techniques de Saint-Jérôme, Marseille, 
France. NMR spectra were recorded on a Bruker ARX 200 spectrometer at the Faculté de Pharmacie 
de Marseille (200 MHz 1H-NMR: reference CHCl3 δ = 7.26, DMSO-d6 δ = 2.50 and 50 MHz 13C: 
reference CHCl3 δ = 76.9, DMSO-d6 δ = 39.5). Solvents were dried by conventional methods. The 
following adsorbent was used for column chromatography: silica gel 60 (Merck, particle size  
0.063–0.200 mm, 70–230 mesh ASTM). TLC was performed on 5 cm × 10 cm aluminium plates 
coated with silica gel 60F-254 (Merck) in an appropriate eluent. Visualization was made with 
ultraviolet light (234 nm). HRMS spectra were recorded on QStar Elite (Applied Biosystems SCIEX) 
spectrometer. PEG was the matrix for HRMS. The experimental exact mass was given for the ion 
which has the maximum isotopic abundance. Purity of synthetized compounds was checked with  
LC-MS analyses which were realized at the Faculty of Pharmacy of Marseille with a Thermo Scientific 
Accela High Speed LC System® coupled with a single quadrupole mass spectrometer Thermo MSQ 
Plus®. The RP-HPLC column used is a Thermo Hypersil Gold® 50 × 2.1 mm (C18 bounded), with 
particles of 1.9 µm diameter. The volume of sample injected on the column was 1 µL. The 
chromatographic analysis, total duration of 8 min, is made with the gradient of following solvents:  
t = 0 min, water/methanol 50/50; 0 < t < 4 min, linear increase in the proportion of water to a ratio 
water/methanol 95/5; 4 < t < 6 min, water/methanol 95/5; 6 < t < 7 min, linear decrease in the 
proportion of water to return to a ratio 50/50 water/methanol; 6 < t < 7 min, water/methanol 50/50. The 
water used was buffered with 5 mM ammonium acetate. The retention times (Tr) of the molecules 
analyzed are indicated in min. The microwave reactions were performed using a Biotage Initiator 
Microwave oven using 10–20 mL sealed vials; temperatures were measured with an IR-sensor and 
reaction times given as hold times. The preparation of 4-chloro-2-trichloromethylquinazoline (4) was 
achieved as described in the literature [29]. 
3.2. Preparation of 4-Amino-2-trichloromethylquinazoline (7) 
Method (A) To a stirred solution of 4-chloro-2-trichloromethylquinazoline (4, 2.0 g, 7.1 mmol) in 
dry THF (10 mL) under nitrogen at rt, was added ammonia solution in methanol (2.0 M, 10.6 mL,  
21.3 mmol, 3 equiv.). The resulting mixture was stirred at this temperature for 3 days, and then, the 
volatiles were removed under vacuum. The residue was triturated with dichloromethane and filtered to 
give 7 as a white solid (1.7 g, 91%). 
Method (B) In a microwave vial equipped with a magnetic stir bar, 4-chloro-2-
trichloromethylquinazoline (4, 700 mg, 2.48 mmol) and ammonia solution in THF (0.4 M, 18.6 mL, 
7.45 mmol, 3 equiv.). The vial was capped and the suspension was then heated at 140 °C for 15 min  
(8 bar). The volatiles were removed under vacuum. The residue was poured into EtOAc (100 mL) and 
extracted two times with brine (30 mL). The organic layer was dried with Na2SO4, filtered and 
evaporated to afford 2 as white solid (650 mg, 100%). M.p. 199 °C. 1H-NMR (DMSO-d6): δ 8.33–8.27 
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(m, 3H), 7.90–7.77 (m, 2H), 7.65–7.57 (m, 1H). 13C-NMR (DMSO-d6): δ 163.2, 160.9, 148.8, 134.1, 
128.3, 127.5, 123.9, 113.4, 98.4. LC-MS (ESI) Tr 2.37 min, m/z [M+H]+ Calcd: 261.96, Found: 
262.03. Anal. calcd. for C9H6Cl3N3: C, 41.18; H, 2.30; N, 16.01. Found: C, 41.43; H, 2.31; N, 16.29.  
3.3. General Procedure for the Preparation of Compounds 8a to 8t 
To a slurry of 60% sodium hydride in oil (152 mg, 3.81 mmol, 5 equiv.) in dry THF (4 mL) at 0 °C 
was slowly added 4-amino-2-trichloromethylquinazoline (7, 200 mg, 0.76 mmol, 1 equiv.). After  
30 min of stirring at rt, the mixture was cooled again and the appropriate sulfonyl chloride (1.52 mmol, 
2 equiv.) was added portionwise. After this addition, the reaction was then stirred at rt until the 
disappearance of starting material. The excess of NaH was hydrolyzed with ice at 0 °C. The mixture 
was extracted with EtOAc and washed three times with brine. The organic layer was dried with 
Na2SO4, filtered and evaporated. The crude residue was triturated in dichloromethane and filtered to 
give the corresponding sulfonamide 8. 
N-(2-Trichloromethylquinazolin-4-yl)benzenesulfonamide (8a). White solid (62%). M.p. 200 °C.  
1H-NMR (DMSO-d6): δ 8.27 (d, J = 8.0 Hz, 1H), 8.02 (t, J = 3.5 Hz, 2H), 7.75–7.60 (m, 2H), 7.48 (t, 
J = 7.0 Hz, 1H), 7.38–7.35 (m, 3H). 13C-NMR (DMSO-d6): δ 163.1, 160.3, 148.6, 144.8, 132.5, 130.0, 
127.8, 127.5, 127.1, 126.4, 125.4, 119.1, 98.9. LC-MS (ESI) Tr 1.36 min, m/z [M+H]+ Calcd: 401.96, 
Found: 401.96. HRMS (ESI+) m/z 423.9454 [M+Na]+, calcd. for C15H10N3O2SCl3: 423.9452 [M+Na]+. 
4-Methyl-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8b). White solid (51%).  
M.p. > 260 °C. 1H-NMR (DMSO-d6): δ 8.24 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 7.6 Hz, 2H), 7.69–7.58 
(m, 2H); 7.45 (t, J = 7.6 Hz, 1H), 7.15 (d, J = 7.6 Hz, 2H), 2.27 (s, 3H). 13C-NMR (DMSO-d6): δ 
163.2, 160.5, 148.6, 142.2, 139.6, 132.3; 127.9, 127.8, 127.0, 126.2, 125.4, 119.4, 99.1; 20.9. LC-MS 
(ESI) Tr 1.98 min, m/z [M−H]− Calcd: 413.97, Found: 414.35. HRMS (ESI+) m/z 437.9607 [M+Na]+, 
calcd. for C16H12N3O2SCl3: 437.9608 [M+Na]+. 
4-Methoxy-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8c). White solid (56%). M.p. 196 °C. 
1H-NMR (DMSO-d6): δ 8.23 (d, J = 7.8 Hz, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.69–7.61 (m, 2H); 7.45 (t, 
J = 7.2 Hz, 1H), 6.87 (d, J = 8.4 Hz, 2H), 3.73 (s, 3H). 13C-NMR (DMSO-d6): δ 163.1, 160.5, 148.6, 
137.2, 132.2, 129.8; 127.0, 126.2, 125.4, 119.4, 112.5, 99.1; 55.3. LC-MS (ESI) Tr 1.29 min, m/z 
[M+H]+ Calcd: 431.97, Found: 431.90. HRMS (ESI+) m/z 453.9559 [M+Na]+, calcd. for 
C16H12N3O3SCl3: 453.9557 [M+Na]+. 
4-Cyano-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8d). Beige solid (73%). M.p. 204 °C. 
1H-NMR (DMSO-d6): δ 8.34 (d, J = 7.8 Hz, 1H), 8.15 (d, J = 8.2 Hz, 2H), 7.87 (d, J = 8.4 Hz, 2H), 
7.82–7.67 (m, 2H); 7.55 (dt, J = 1.5 Hz, J = 8.2 Hz, 1H). 13C-NMR (DMSO-d6): δ 162.6, 159.8, 148.8, 
148.6, 133.2, 132.1, 128.4; 127.4, 127.1, 125.2, 118.4, 118.3, 112.8, 98.3. LC-MS (ESI) Tr 1.19 min, 
m/z [M−H]− Calcd: 424.95, Found: 425.39. HRMS (ESI+) m/z 448.9406 [M+Na]+, calcd. for 
C16H9N4O2SCl3: 448.9404 [M+Na]+. 
4-Chloro-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8e). White solid (50%).  
M.p. > 260 °C. 1H-NMR (DMSO-d6): δ 8.25 (d, J = 7.6 Hz, 1H), 7.99 (d, J = 8.2 Hz, 2H), 7.71–7.63 
Molecules 2012, 17 8113 
 
(m, 2H); 7.48–7.39 (m, 3H). 13C-NMR (DMSO-d6): δ 163.2, 160.2, 148.6, 144.0, 134.5, 132.5, 129.6; 
127.5, 127.0, 126.4, 125.3, 119.1, 98.8. LC-MS (ESI) Tr 2.54 min, m/z [M+H]+ Calcd: 435.92, Found: 
435.85. HRMS (ESI+) m/z 437.9211 [M+H]+, calcd. for C15H9N3O2SCl4: 436.9141.  
4-Bromo-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8f). White solid (60%).  
M.p. > 260 °C. 1H-NMR (DMSO-d6): δ 8.25 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.72–7.45 
(m, 5H). 13C-NMR (DMSO-d6): δ 163.4, 160.3, 148.6, 144.5, 132.5, 130.5, 129.9; 127.1, 126.4, 125.4, 
123.3, 119.3, 98.9. LC-MS (ESI) Tr 2.60 min, m/z [M+H]+ Calcd: 479.87, Found: 480.52. HRMS 
(ESI+) m/z 503.8534 [M+Na]+, calcd. for C15H9BrN3O2SCl3: 503.8532 [M+Na]+. 
4-Fluoro-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8g). White solid (66%).  
M.p. > 260 °C. 1H-NMR (DMSO-d6): δ 8.25 (d, J = 8.0 Hz, 1H), 8.10–8.03 (m, 2H), 7.75–7.60 (m, 
2H), 7.48 (t, J = 7.1 Hz, 1H), 7.17 (t, J = 8.9 Hz, 2H). 13C-NMR (DMSO-d6): δ 165.4, 163.4, 160.3, 
148.6, 141.5 (d, J = 2.9 Hz), 132.4, 130.5 (d, J = 8.8 Hz), 127.1, 126.4, 125.4, 119.3, 114.3 (d,  
J = 21.8 Hz), 98.9. LC-MS (ESI) Tr 1.81 min, m/z [M+H]+ Calcd: 419.95, Found: 419.79. HRMS 
(ESI+) m/z 419.9534 [M+H]+, calcd. for C15H9N3O2SCl3F: 418.9465. 
3-Fluoro-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8h). White solid (53%). M.p. 194 °C. 
1H-NMR (DMSO-d6): δ 8.30 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.77–7.65 (m, 3H), 7.53 (t, 
J = 7.8 Hz, 1H), 7.44–7.38 (m, 1H), 7.25 (t, J = 8.2 Hz, 1H). 13C-NMR (DMSO-d6): δ 163.6, 162.8, 
160.1, 158.8, 148.6, 146.8 (d, J = 6.5Hz), 132.9, 129.9 (d, J = 7.6 Hz), 127.1 (d, J = 21.3 Hz), 125.3, 
123.4 (d, J = 2.9 Hz), 118.6, 117.3 (d, J = 20.9 Hz), 115.4 (d, J = 23.4 Hz), 98.5. LC-MS (ESI) Tr 
1.69 min, m/z [M+H]+ Calcd: 419.95, Found: 419.81. HRMS (ESI+) m/z 441.9359 [M+Na]+, calcd. for 
C15H9N3O2SCl3F: 441.9357 [M+Na]+. 
2-Fluoro-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8i). White solid (60%). M.p. 188 °C. 
1H-NMR (DMSO-d6): δ 8.28 (d, J = 8.0 Hz, 1H), 8.06 (dt, J = 1.5 Hz, J = 7.6 Hz, 1H), 7.78–7.61 (m, 
2H), 7.50 (dt, J = 1.6 Hz, J = 7.6 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 7.07 (t, J = 8.9 Hz, 1H). 13C-NMR 
(DMSO-d6): δ 163.4, 160.3, 158.0 (d, J = 248.8 Hz), 148.7, 133.1 (d, J = 15.3 Hz), 132.6, 132.0 (d,  
J = 8.1 Hz), 131.8, 127.1, 126.4, 125.4, 123.5 (d, J = 3.6 Hz), 119.0; 115.7 (d, J = 21.9 Hz), 98.5.  
LC-MS (ESI) Tr 1.25 min, m/z [M+H]+ Calcd: 419.95, Found: 419.80. HRMS (ESI+) m/z 441.9360 
[M+Na]+, calcd. for C15H9N3O2SCl3F: 441.9357 [M+Na]+. 
4-Nitro-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8j). Yellow solid (91%). M.p. 250 °C. 
1H-NMR (DMSO-d6): δ 8.30–8.20 (m, 5H), 7.78–7.71 (m, 2H), 7.51 (d, J = 7.2 Hz, 1H). 13C-NMR 
(DMSO-d6): δ 163.6, 160.0, 151.6, 148.6, 148.0, 132.7, 128.9; 127.1, 126.6, 125.4, 123.0, 119.1, 98.6. 
LC-MS (ESI) Tr 1.87 min, m/z [M−H]− Calcd: 444.94, Found: 445.16. HRMS (ESI+) m/z 468.9306 
[M+Na]+, calcd. for C15H9N4O4SCl3: 468.9302 [M+Na]+. 
3-Nitro-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8k). Beige solid (56%). M.p. 204 °C. 
1H-NMR (DMSO-d6): δ 8.76 (s, 1H), 8.30–8.21 (m, 3H), 7.74–7.61 (m, 3H), 7.51 (t, J = 7.6 Hz, 1H). 
13C-NMR (DMSO-d6): δ 163.5, 160.1, 148.5, 147.3, 147.1, 133.6, 132.7; 129.6, 127.2, 126.7, 125.4, 
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124.6, 123.2, 119.1, 98.5. LC-MS (ESI) Tr 1.40 min, m/z [M−H]− Calcd: 444.94, Found: 445.17. 
HRMS (ESI+) m/z 468.9303 [M+Na]+, calcd. for C15H9N4O4SCl3: 468.9302 [M+Na]+. 
2-Nitro-N-(2-trichloromethylquinazolin-4-yl)benzenesulfonamide (8l). Beige solid (59%). M.p. > 260 °C. 
1H-NMR (DMSO-d6): δ 8.34–8.25 (m, 2H), 7.75–7.53 (m, 6H). 13C-NMR (DMSO-d6): δ 163.7, 160.2, 
148.7, 147.9, 137.3, 132.7, 131.8; 131.0, 130.7, 127.1, 126.5, 125.5, 122.2, 119.1, 98.5. LC-MS (ESI) 
Tr 1.16 min, m/z [M−H]− Calcd: 444.94, Found: 445.25. HRMS (ESI+) m/z 468.9303 [M+Na]+, calcd. 
for C15H9N4O4SCl3: 468.9302 [M+Na]+. 
N-(2-trichloromethylquinazolin-4-yl)-4-(trifluoromethyl)benzenesulfonamide (8m). White solid (88%). 
M.p. 166 °C. 1H-NMR (DMSO-d6): δ 8.28 (d, J = 7.6 Hz, 1H), 8.13 (d, J = 7.2 Hz, 2H), 7.74–7.50 (m, 
5H). 13C-NMR (DMSO-d6): δ 163.5, 160.2, 149.4, 148.6, 132.6, 129.8 (q, J = 31.8 Hz), 128.3, 127.1, 
126.5, 125.4, 124.8 (q, J = 3.7 Hz), 124.0 (q, J = 271.0 Hz), 119.5, 98.6. LC-MS (ESI) Tr 2.80 min, 
m/z [M+H]+ Calcd: 469.94, Found: 469.82. HRMS (ESI+) m/z 491.9328 [M+Na]+, calcd. for 
C16H9F3N3O2SCl3: 491.9325 [M+Na]+. 
N-(2-trichloromethylquinazolin-4-yl)-3-(trifluoromethyl)benzenesulfonamide (8n). White solid (100%). 
M.p. 255 °C. 1H-NMR (DMSO-d6): δ 8.44 (d, J = 8.0 Hz, 1H), 8.33–8.29 (m, 2H), 7.91–7.82 (m, 3H); 
7.76 (d, J = 8.0 Hz, 1H), 7.70–7.62 (m, 1H). 13C-NMR (DMSO-d6): δ 160.6, 159.3, 148.7, 143.9, 
134.1, 131.5, 130.0, 129.1 (q, J = 32.2 Hz), 128.4 (q, J = 3.5 Hz), 128.0, 127.8, 124.7, 124.4 (q,  
J = 4.1 Hz), 123.7 (q, J = 271 Hz), 116.6, 97.5. LC-MS (ESI) Tr 2.53 min, m/z [M+H]+ Calcd: 469.94, 
Found: 469.76. HRMS (ESI+) m/z 469.9502 [M+H]+, calcd. for C16H9F3N3O2SCl3: 468.9433. 
N-(2-trichloromethylquinazolin-4-yl)-2-(trifluoromethyl)benzenesulfonamide (8o). White solid (50%). 
M.p. 205 °C. 1H-NMR (DMSO-d6): δ 8.71 (d, J = 8.2 Hz, 1H), 8.51 (d, J = 7.2 Hz, 1H), 8.04–7.82 (m, 
6H). 13C-NMR (DMSO-d6): δ 158.2, 158.1, 148.5, 138.8, 135.4, 133.4, 133.3, 132.8, 129.3, 128.2, 
128.0 (q, J = 6.3 Hz), 125.7 (q, J = 32.8 Hz), 124.1, 122.9 (q, J = 272.4 Hz), 114.2, 96.3. LC-MS 
(ESI) Tr 2.17 min, m/z [M+H]+ Calcd: 469.94, Found: 469.76. HRMS (ESI+) m/z 491.9327 [M+Na]+, 
calcd. for C16H9F3N3O2SCl3: 491.9325 [M+Na]+. 
N-(2-trichloromethylquinazolin-4-yl)biphenyl-4-sulfonamide (8p). White solid (23%). M.p. 210 °C. 
1H-NMR (DMSO-d6): δ 8.29 (d, J = 7.8 Hz, 1H), 8.11 (d, J = 8.2 Hz, 2H), 7.73–7.65 (m, 6H),  
7.62–7.36 (m, 4H). 13C-NMR (DMSO-d6): δ 163.0, 160.3, 148.6, 143.8, 141.8, 139.6, 132.5, 129.0, 
128.5, 127.8, 127.1, 126.9, 126.5, 125.9, 125.4, 119.1, 98.9. LC-MS (ESI) Tr 3.06 min, m/z [M−H]− 
Calcd: 475.99, Found: 476.30. HRMS (ESI+) m/z 499.9762 [M+Na]+, calcd. for C21H14N3O2SCl3: 
499.9765 [M+Na]+. 
N-(2-trichloromethylquinazolin-4-yl)naphtalene-2-sulfonamide (8q). Beige solid (43%). M.p. 206 °C. 
1H-NMR (DMSO-d6): δ 8.65 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.85 (d,  
J = 8.5 Hz, 2H), 7.60–7.48 (m, 5H). 13C-NMR (DMSO-d6): δ 163.3, 160.4, 148.6, 142.3, 133.4, 132.4, 
131.8, 128.8, 128.0, 127.5, 127.1, 126.4, 126.3, 125.4, 124.6, 119.3, 98.8. LC-MS (ESI) Tr 2.39 min, 
m/z [M+H]+ Calcd: 451.97, Found: 451.79. HRMS (ESI+) m/z 451.9785 [M+H]+, calcd. for 
C19H12N3O2SCl3: 450.9716. 
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N-(2-trichloromethylquinazolin-4-yl)naphtalene-1-sulfonamide (8r). White solid (61%). M.p. > 260 °C. 
1H-NMR (DMSO-d6): δ 8.86 (d, J = 7.8 Hz, 1H), 8.43–8.33 (m, 2H), 7.95–7.84 (m, 2H), 7.68–7.42 
(m, 6H). 13C-NMR (DMSO-d6): δ 163.4, 160.3, 148.7, 141.0, 133.3, 132.3, 130.6, 129.3, 128.5, 128.0, 
127.0, 126.4, 126.3, 126.1, 125.5, 125.3, 124.5, 119.1, 98.7. LC-MS (ESI) Tr 2.32 min, m/z [M+H]+ 
Calcd: 451.97, Found: 451.64. HRMS (ESI+) m/z 473.9608 [M+Na]+, calcd. for C19H12N3O2SCl3: 
473.9608 [M+Na]+. 
N-(2-trichloromethylquinazolin-4-yl)thiophene-2-sulfonamide (8s). Beige solid (43%). M.p. 191 °C. 
1H-NMR (DMSO-d6): δ 8.23 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 3.0 Hz, 1H), 7.77–7.62 (m, 2H),  
7.57–7.45 (m, 2H), 6.97 (t, J = 4.2 Hz, 1H). 13C-NMR (DMSO-d6): δ 163.5, 160.5, 148.7, 146.7, 
146.9, 132.5, 130.6, 128.8, 127.1, 126.4, 126.1, 125.4, 119.4, 99.0. LC-MS (ESI) Tr 1.07 min, m/z 
[M+H]+ Calcd: 407.91, Found: 407.86. HRMS (ESI+) m/z 429.9014 [M+Na]+, calcd. for 
C13H8N3O2S2Cl3: 429.9016 [M+Na]+. 
N-(2-trichloromethylquinazolin-4-yl)methanesulfonamide (8t). White solid (18%). M.p. 186 °C.  
1H-NMR (DMSO-d6): δ 8.47 (d, J = 8.0 Hz, 1H), 7.97–7.92 (m, 2H), 7.72 (t, J = 6.2 Hz, 1H), 3.67 (s, 
3H). 13C-NMR (DMSO-d6): δ 158.6, 158.2, 149.1, 135.5, 129.3, 128.7, 123.9, 113.7, 97.0, 42.1.  
LC-MS (ESI) Tr 0.82 min, m/z [M+H]+ Calcd: 339.94, Found: 339.89. HRMS (ESI+) m/z 339.9475 
[M+H]+, calcd. for C10H8N3O2SCl3: 338.9403. 
4. Conclusions  
A series of 20 quinazolines was synthetized by an efficient two-step strategy. Firstly, 4-amino-2-
trichloromethylquinazoline (7) was prepared in quantitative yield from the corresponding 4-chloro 
derivative under microwave irradiation. Then, the key amino intermediate 7 was reacted with various 
sulfonyl chlorides in the presence of NaH, leading to the expected sulfonamides 8. Synthesized 
compounds were highly soluble in biological media, less-toxic toward the human HepG2 cell line than 
previously identified hits but did not display significant in vitro antiplasmodial activity. 
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